AUS
NZ
UK
CA
USA
IND
Healthcare
ASX Healthcare Small-Cap: Could Alcidion Be Near a Breakout?
April 30, 2026 11:04 AM AEST| By SamAlcidion gains attention with strong contract momentum, positive cash flow, and expanding healthcare IT platform, highlighting growth potential alongside typical small-cap volatility in the Australian market.
ASX 200 Telix Pharma Valuation in Focus Now?
April 30, 2026 08:08 AM AEST| By SamTelix Pharmaceuticals operates within the biotechnology sector, focusing on radiopharmaceutical development, valuation context, and global healthcare innovation trends across evolving market frameworks.
ASX All Ordinaries Update: Mesoblast (ASX:MSB) Trial Progress Shift?
April 29, 2026 04:45 PM AEST| By SamMesoblast advances clinical trial progress within regenerative medicine, highlighting biotechnology innovation and healthcare sector activity across the ASX All Ordinaries.
ASX All Ordinaries Update: Imugene (ASX:IMU) Biotech Milestone Impact?
April 29, 2026 04:03 PM AEST| By SamImugene’s clinical milestone highlights biotech progress within the ASX All Ordinaries, showcasing innovation, research development, and evolving healthcare sector dynamics.
ASX 200 Healthcare Shakeout: Which Giant Is Rebuilding Faster?
April 29, 2026 02:10 PM AEST| By SamCSL, Cochlear and Pro Medicus face pressure amid a healthcare sector reset, with valuation declines, mixed sentiment, and evolving market conditions shaping their recovery outlook.
ASX 200 Giant Under Pressure: What’s Behind CSL’s Slide?
April 29, 2026 02:06 PM AEST| By SamCSL shares fall to a multi-year low amid sector rotation and vaccine concerns, while its core plasma business continues to support long-term growth within the healthcare sector.
Is ASX 100 Healthcare Stock Cochlear Expanding Share Plan?
April 29, 2026 01:42 PM AEST| By SamCochlear advances an employee share initiative, highlighting corporate governance practices and workforce alignment within the healthcare technology sector.
Watch ASX 300 Health Stock as Syntara Advances Trial
April 29, 2026 01:28 PM AEST| By SamSyntara advances oncology clinical development through funding initiatives, highlighting biotechnology sector activity and the progression of medical research within Australian equities.
ASX High-Flyers Pause: Are 4DMedical and EOS Losing Steam?
April 29, 2026 10:46 AM AEST| By Sam4DMedical and EOS see pullbacks after strong rallies, highlighting how rising expectations, valuation concerns, and shifting sentiment can drive volatility in high-growth Australian stocks.
Small-Cap Surprise: This ASX Healthcare Stock Turning Heads
April 29, 2026 10:27 AM AEST| By SamBiome Australia’s expanding probiotic business, distribution growth, and operational changes highlight its evolving position within the healthcare sector and broader Australian share market.
Why Is (ASX:DXB) Dimerix Advancing Its Phase 3 Strategy?
April 28, 2026 08:07 PM AEST| By SamDimerix advances its Phase 3 kidney disease trial with improved design clarity, regulatory alignment, and steady progress, setting the stage for a crucial clinical outcome.
Why Is (ASX:AVR) Advancing Its Heart Valve Study in the US?
April 28, 2026 08:01 PM AEST| By Sam(ASX:AVR) gains US Medicare support for its global valve trial, boosting study expansion and strengthening progress in advanced heart disease treatment innovation.
ASX 200: Most Shorted Stocks and Shifting Sentiment in Week Eighteen
April 28, 2026 06:19 PM AEST| By Team Kalkine MediaShort interest trends across ASX stocks highlight shifting positioning in biotech, mining, and consumer sectors, with Telix leading activity amid notable corporate developments.
What’s Driving the Leadership Shift at (ASX:EVE)?
April 28, 2026 06:15 PM AEST| By SamEVE Health Group reshapes leadership to accelerate commercialisation, strengthen regulatory focus, and advance drug reformulation strategy within the evolving healthcare sector.
ASX 200 Today Watch: Is This Biotech Near Breakthrough?
April 28, 2026 04:44 PM AEST| By Team Kalkine MediaBiotech innovation continues to evolve as companies advance clinical and commercial strategies, highlighting the growing importance of regenerative medicine within Australia’s dynamic market landscape.
ASX 200 Healthcare Update: Pro Medicus vs Cochlear
April 28, 2026 04:10 PM AEST| By SamPro Medicus and Cochlear highlight activity within the ASX healthcare sector, reflecting medical technology development and integration into global healthcare systems.
What Is Driving Strong Clinical Momentum for Orthocell?
April 28, 2026 03:22 PM AEST| By SamOrthocell’s Remplir gains attention with strong clinical outcomes, expanding adoption, and supportive reimbursement, highlighting its growing role in nerve repair and regenerative healthcare innovation.
Top 3 Healthcare Shares Driving ASX 200 Today Sector Momentum
April 28, 2026 03:03 PM AEST| By SamASX healthcare stocks reflect sector resilience, driven by innovation, global operations, and consistent demand, with major companies maintaining strong presence across key indices.
Why Are ASX Healthcare Shares Drawing Fresh Attention?
April 28, 2026 02:41 PM AEST| By SamASX healthcare shares face pressure, yet select companies like Sigma Healthcare, Polynovo, and Pro Medicus continue to show resilience through innovation, operational strength, and expanding global presence.
ASX Healthcare Update: Island Pharma Expands Capital Base
April 28, 2026 01:50 PM AEST| By SamIsland Pharmaceuticals’ new share listing reflects ongoing capital management, supporting financial flexibility within the healthcare sector as companies continue to fund development and operational growth.
Advertise your brand on Kalkine Media